rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Monopar Therapeutics Inc.

MNPR · Nasdaq

Health CareBiotechnologyNot moving yet

MNPR stood above a rising 150-day average in 26 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 15.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$105K
Insider sales, 12 months
$9.3M
Officials’ trades on record
0
Institutions holding
95 (+16)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 26 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$33.7M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months8
Buyers · sellers1 · 6
WhoDidSharesTraded
Christopher M. StarrDirectorsold4,631at $78.091 Oct 2026filed 5 Oct 2026
Christopher M. StarrDirectorsold2,970at $78.821 Oct 2026filed 5 Oct 2026
Christopher M. StarrDirectorsold799at $79.671 Oct 2026filed 5 Oct 2026
Chandler RobinsonChief Executive Officersold10,450at $87.1524 Sep 2026filed 28 Sep 2026
Chandler RobinsonChief Executive Officersold9,638at $87.9624 Sep 2026filed 28 Sep 2026
Chandler RobinsonChief Executive Officersold8,368at $88.9724 Sep 2026filed 28 Sep 2026
Chandler RobinsonChief Executive Officersold600at $89.7924 Sep 2026filed 28 Sep 2026
Kim R. TsuchimotoDirectorsold485at $108.8326 Aug 2026filed 27 Aug 2026
Kim R. TsuchimotoDirectorsold615at $109.5626 Aug 2026filed 27 Aug 2026
Kim R. TsuchimotoDirectorsold700at $110.6526 Aug 2026filed 27 Aug 2026
Kim R. TsuchimotoDirectorsold1,098at $111.8426 Aug 2026filed 27 Aug 2026
Kim R. TsuchimotoDirectorsold602at $112.9326 Aug 2026filed 27 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders95+16 on the quarter
New · exited33 · 16
Reported value$576.4M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20261,312,129$121.7M+1,312,129
RA CAPITAL MANAGEMENT, L.P.unchanged · filed 14 Aug 2026667,207$61.8M00.0%
BlackRock, Inc.added · filed 7 Aug 2026348,819$32.3M+32,252+10.2%
DEERFIELD MANAGEMENT COMPANY, L.P.unchanged · filed 14 Aug 2026323,745$30.0M00.0%
Saturn V Capital Management LPreduced · filed 14 Aug 2026311,976$28.9M-33,650−9.7%
Siren, L.L.C.unchanged · filed 13 Aug 2026270,118$25.0M00.0%
ADAR1 Capital Management, LLCreduced · filed 14 Aug 2026217,595$20.1M-46,683−17.7%
Polar Capital Holdings Plcreduced · filed 14 Aug 2026214,469$19.9M-12,057−5.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026209,711$19.4M-8,752−4.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.reduced · filed 14 Aug 2026209,195$19.4M-100,000−32.3%
30 Sep 2024 – 30 Jun 2026
95192Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christopher M. Starr Company insiderDirector · last 1 Oct 20260 · 2
Andrew Cittadine Company insiderChief Operating Officer · last 30 Sep 202612 · 0
Chandler Robinson Company insiderChief Executive Officer · last 30 Sep 20260 · 2
Quan Anh Vu Company insiderChief Financial Officer · last 30 Sep 20261 · 0
Kim R. Tsuchimoto Company insiderDirector · last 26 Aug 20261 · 3
Patrice Rioux Company insiderOther · last 26 Aug 20260 · 1
Raymond Anderson Company insiderDirector · last 25 Aug 20260 · 2
Nicole Sweeny Company insiderDirector · last 26 Jun 20260 · 0
Susan Rodriguez Company insiderCCSO · last 2 Mar 20260 · 0
Arthur J. Klausner Company insiderDirector · last 18 Dec 20250 · 1
Diane Hendricks Company insider10% owner · last 16 Dec 20251 · 0
Lavina Talukdar Company insiderDirector · last 2 Dec 20250 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-12.1%
Share count trendFY 2025 · to 17 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$61.8M

Analyst forecasts

No analyst forecasts yet.